Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2012

Global Markets Direct, April 2012, Pages: 119

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2012', provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutic pipeline. This report provides information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury). 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Renal Failure (ARF) (Acute Kidney Injury).
- A review of the Acute Renal Failure (ARF) (Acute Kidney Injury) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutic Products under Development, Key Players in Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics, Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Overview, Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline, Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Renal Failure (ARF) (Acute Kidney Injury) Overview
Therapeutics Development
An Overview of Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury)
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics under Development by Companies
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics – Products under Development by Companies
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics Development
FibroGen, Inc.
Novartis AG
Bayer AG
Cleveland BioLabs, Inc.
Torrent Pharmaceuticals Limited
Am-Pharma B.V.
AlloCure Inc.
Angion Biomedica Corp.
Thrasos, Inc.
CorMedix, Inc.
Exponential Biotherapies, Inc.
Action Pharma A/S
Kringle Pharma, Inc.
Nephrx Corporation
Acute Renal Failure (ARF) (Acute Kidney Injury) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
FG-3019 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Protectan CBLB502 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bovine Alkaline Phosphatase (iv) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EA-230 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EA-230 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BB3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QPI 1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Eculizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ChronSeal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lenalidomide + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-Acetylcysteine + Deferoxamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bortezomib + Dexamethasone + Doxorubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acetylcysteine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erythropoietin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib Mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AP214 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atorvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sodium Bicarbonate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Velcade + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bendavia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fenoldopam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketanserin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CRMD-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NX001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Curcumin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nautiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pentoxifylline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Selenium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fenoldopam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Furosemide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BCT197 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mesenchymal Stromal Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HIF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THR-184 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AC607 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Intravenous Recombinant Alkaline Phosphatase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BR-5489 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human HGF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics – Drug Profile Updates
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics – Discontinued Products
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics - Dormant Products
Acute Renal Failure (ARF) (Acute Kidney Injury) – Product Development Milestones
Featured News & Press Releases
Jan 05, 2012: AlloCure's Investigational Treatment For Acute Kidney Injury Receives Fast Track Designation From FDA
Nov 14, 2011: AlloCure Presents Safety And Preliminary Efficacy Of AC607 For Treatment Of Acute Kidney Injury At American Society Of Nephrology
Oct 03, 2011: Journal of Immunology Publishes Study Of Cleveland BioLabs's CBLB502 In Acute Renal Ischemic Failure
Sep 26, 2011: Action Pharma’s Phase IIb Clinical Trial With AP214 To Prevent Kidney Injury Associated With Major Cardiac Surgery Demonstrates Positive Top-Line Results
Sep 13, 2011: Thrasos Initiates Phase I Clinical Trial Of THR-184 In Acute Kidney Injury
Aug 08, 2011: Final Patient Completes Last Visit In Action Pharma’s Phase IIb Clinical Trial Of Ap214
Jun 21, 2011: CorMedix Announces SPA Agreement With FDA For Phase III Trial Of CRMD001 Study In Prevention Of CI-AKI
May 09, 2011: Action Pharma Completes Dosing In Phase IIb Clinical Trial With AP214 To Prevent Acute Kidney Injury Undergoing Cardiac Surgery
Jul 06, 2010: Angion Biomedica Receives Fast Track And Orphan Drug Designations From FDA For BB3
Mar 10, 2010: AM-Pharma Presents Positive Results of Its Phase II Clinical Trial With Alkaline Phosphatase in Acute Kidney Injury At The ISICEM Conference In Brussels
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2012
Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
FibroGen, Inc., H1 2012
Novartis AG, H1 2012
Bayer AG, H1 2012
Cleveland BioLabs, Inc., H1 2012
Torrent Pharmaceuticals Limited, H1 2012
Am-Pharma B.V., H1 2012
AlloCure Inc., H1 2012
Angion Biomedica Corp., H1 2012
Thrasos, Inc., H1 2012
CorMedix, Inc., H1 2012
Exponential Biotherapies, Inc., H1 2012
Action Pharma A/S, H1 2012
Kringle Pharma, Inc., H1 2012
Nephrx Corporation, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics – Drug Profile Updates
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics – Discontinued Products
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2012
Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013